全文获取类型
收费全文 | 39806篇 |
免费 | 5887篇 |
国内免费 | 298篇 |
专业分类
耳鼻咽喉 | 875篇 |
儿科学 | 1273篇 |
妇产科学 | 1299篇 |
基础医学 | 4189篇 |
口腔科学 | 995篇 |
临床医学 | 5357篇 |
内科学 | 8589篇 |
皮肤病学 | 951篇 |
神经病学 | 3549篇 |
特种医学 | 1464篇 |
外科学 | 6482篇 |
综合类 | 549篇 |
现状与发展 | 2篇 |
一般理论 | 51篇 |
预防医学 | 4143篇 |
眼科学 | 801篇 |
药学 | 2610篇 |
中国医学 | 25篇 |
肿瘤学 | 2787篇 |
出版年
2023年 | 708篇 |
2022年 | 391篇 |
2021年 | 802篇 |
2020年 | 1102篇 |
2019年 | 775篇 |
2018年 | 1262篇 |
2017年 | 1106篇 |
2016年 | 1321篇 |
2015年 | 1261篇 |
2014年 | 1721篇 |
2013年 | 2118篇 |
2012年 | 1923篇 |
2011年 | 1962篇 |
2010年 | 1490篇 |
2009年 | 1604篇 |
2008年 | 1699篇 |
2007年 | 1707篇 |
2006年 | 1729篇 |
2005年 | 1550篇 |
2004年 | 1365篇 |
2003年 | 1312篇 |
2002年 | 1239篇 |
2001年 | 975篇 |
2000年 | 947篇 |
1999年 | 897篇 |
1998年 | 568篇 |
1997年 | 534篇 |
1996年 | 580篇 |
1995年 | 557篇 |
1994年 | 428篇 |
1993年 | 358篇 |
1992年 | 686篇 |
1991年 | 685篇 |
1990年 | 619篇 |
1989年 | 661篇 |
1988年 | 587篇 |
1987年 | 579篇 |
1986年 | 544篇 |
1985年 | 499篇 |
1984年 | 452篇 |
1983年 | 373篇 |
1982年 | 313篇 |
1981年 | 248篇 |
1979年 | 329篇 |
1978年 | 329篇 |
1977年 | 249篇 |
1976年 | 237篇 |
1975年 | 244篇 |
1974年 | 245篇 |
1972年 | 238篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
4.
5.
6.
7.
8.
9.
10.
Jenny U. Johansson Nathaniel S. Woodling Qian Wang Maharshi Panchal Xibin Liang Angel Trueba-Saiz Holden D. Brown Siddhita D. Mhatre Taylor Loui Katrin I. Andreasson 《The Journal of clinical investigation》2015,125(1):350-364
Microglia, the innate immune cells of the CNS, perform critical inflammatory and noninflammatory functions that maintain normal neural function. For example, microglia clear misfolded proteins, elaborate trophic factors, and regulate and terminate toxic inflammation. In Alzheimer’s disease (AD), however, beneficial microglial functions become impaired, accelerating synaptic and neuronal loss. Better understanding of the molecular mechanisms that contribute to microglial dysfunction is an important objective for identifying potential strategies to delay progression to AD. The inflammatory cyclooxygenase/prostaglandin E2 (COX/PGE2) pathway has been implicated in preclinical AD development, both in human epidemiology studies and in transgenic rodent models of AD. Here, we evaluated murine models that recapitulate microglial responses to Aβ peptides and determined that microglia-specific deletion of the gene encoding the PGE2 receptor EP2 restores microglial chemotaxis and Aβ clearance, suppresses toxic inflammation, increases cytoprotective insulin-like growth factor 1 (IGF1) signaling, and prevents synaptic injury and memory deficits. Our findings indicate that EP2 signaling suppresses beneficial microglia functions that falter during AD development and suggest that inhibition of the COX/PGE2/EP2 immune pathway has potential as a strategy to restore healthy microglial function and prevent progression to AD. 相似文献